2016ACC/AHA冠心病患者双联抗血小板药物持续时间指南更新(二)2016ACC/AHAGuidelineFocusedUpdateonDurationofDualAntiplateletTherapyinPatientsWithCoronaryArteryDisease八
PCI术后择期非心脏手术的时间管理PCISIHDDESBMS0mo3mo6mo12moClassb:ⅡDiscontinuationafter3momaybereasonableHighbleedingrisksorsignificantovertbleedingClass:ⅠAtleast6mo(clipidogrel)ACSClass:ⅠAtleast1mo(clipidogrel)NohighriskofbleedingandnosignificantovertbleedingonDAPTClassb:Ⅱ>6momaybereasonableClassb:Ⅱ>1momaybereasonableClass:ⅠAtleast12mo(clipidogrel,prasugrel,ticagrelor)NohighriskofbleedingandnosignificantovertbleedingonDAPTClassb:Ⅱ>1ymaybereasonableHighbleedingrisksorsignificantovertbleedingClassb:ⅡDiscontinuationafter6momaybereasonable冠心病患者PCI术后接受DAPT治疗的P2Y12抑制剂的使用流程四
PCISIHD患者PCI术后DAPT治疗维持时间的建议CORLOE建议ⅠASIHD患者裸金属支架(BMS)植入术后DAPT治疗的,P2Y12抑制剂治疗(氯吡格雷)至少维持一个月
ⅠB-RSR